Medtronic plc (NYSE:MDT) announced key board appointments on Tuesday, naming John Groetelaars and Bill Jellison as independent directors, effective immediately. This move comes shortly after Elliott Investment Management became the company’s largest shareholder.
The company also unveiled its new Growth Committee, tasked with overseeing the evaluation and execution of strategic M&A, R&D investments, and potential divestitures, including the planned separation of its Diabetes business.
The medtech giant is scheduled to host an Investor Day in mid-2026, as first reported by The Wall Street Journal.
Also Read: Carlsmed’s Personalized Spine Implants Get Significant Reimbursement Advantage
Medtronic reported strong first-quarter 2026 results, with sales hitting $8.58 billion, surpassing the consensus estimate of $8.38 billion. This marks an 8.4% increase year-over-year, with organic growth of 4.8%.
Adjusted earnings of $1.26 per share also …